Open-label Extension Trial for Pre- and Postmenopausal Women With HSDD.
Phase of Trial: Phase III
Latest Information Update: 26 Jun 2014
At a glance
- Drugs Flibanserin (Primary)
- Indications Decreased libido
- Focus Adverse reactions; Registrational
- Sponsors Sprout Pharmaceuticals
- 14 Mar 2012 Company (Sprout Pharmaceuticals) added as trial sponsor as reported by ClinicalTrials.gov.
- 23 Nov 2010 Status changed from recruiting to discontinued according to ClinicalTrials.gov record.
- 18 Oct 2010 Planned end date changed from 1 Feb 2012 to 1 Jan 2011 as reported by ClinicalTrials.gov.